– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J., June 24, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission...
Hence then, the article about sephience sepiapterin granted marketing authorization by the european commission for the treatment of children and adults living with phenylketonuria pku was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) )
Also on site :
- Stunning ISS Photo of Florida, Cuba Captures & 039;Moonglint& 039;
- Saudi-led coalition strikes Yemeni port over unauthorised weapons shipment
- Will Cristiano Ronaldo play tonight for Al-Nassr vs Al Ettifaq in SPL 2025-26?